Expression of CXCL8 and its relationship with prognosis in patients with non-small cell lung cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Elevated chemokine (CXCL8) levels in non-small cell lung cancer (NSCLC) patients correlate with advanced tumor stage and lymph node metastasis. CXCL8 serves as a biomarker for predicting prognosis and survival in NSCLC.
Area Of Science
- Oncology
- Molecular Biology
- Biomarker Discovery
Background
- Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide.
- Understanding molecular markers associated with NSCLC progression and prognosis is crucial for improved patient outcomes.
- Chemokine (CXCL8) is implicated in various inflammatory and cancer-related processes.
Purpose Of The Study
- To evaluate serum chemokine (CXCL8) expression levels in non-small cell lung cancer (NSCLC) patients.
- To analyze the correlation between CXCL8 expression and clinicopathological characteristics, including lymph node metastasis and tumor staging.
- To assess the prognostic value of CXCL8 for predicting patient survival in NSCLC.
Main Methods
- Retrospective analysis of 149 NSCLC patients.
- Measurement of serum CXCL8 levels upon admission or prior to treatment.
- Statistical analysis including Receiver Operating Characteristic (ROC) curves and Kaplan-Meier survival analysis.
Main Results
- NSCLC patients demonstrated significantly higher serum CXCL8 levels compared to benign tumor controls (P<0.001).
- High CXCL8 expression was associated with a higher incidence of lymph node metastasis and advanced TNM stage (Stage III) in NSCLC (P<0.01).
- CXCL8 was identified as an independent predictor for lymph node metastasis (AUC=0.730) and higher TNM stage (AUC=0.708), and a validated biomarker for five-year survival.
Conclusions
- Serum CXCL8 is significantly elevated in NSCLC and strongly associated with adverse clinicopathological features.
- CXCL8 demonstrates predictive value for lymph node metastasis, tumor staging, and overall survival in NSCLC patients.
- Further research into CXCL8's role in the NSCLC tumor microenvironment is warranted to explore therapeutic potential.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...